Business, energy, technology, markets and global industry news from Business News Today

antiretroviral therapy

PharmaDeviceNews antiretroviral therapy
Representative image of biopharma laboratory research. Gilead Sciences and Merck’s latest Phase 3 updates highlight the promise of once-weekly HIV treatment with islatravir and lenacapavir, while raising fresh questions over Trodelvy’s lung cancer expansion strategy.
Pharma & Biotech

Gilead and Merck pipeline update reveals promise in HIV and pressure in oncology

Gilead and Merck gain HIV momentum but face fresh oncology questions. See why this split pipeline update matters.

Read More
Merck’s IDVYNSO approval adds a new HIV option, but the real battle starts after viral suppression
Pharma & Biotech

FDA approval of IDVYNSO gives Merck a fresh HIV story, but will clinicians switch stable patients?

Merck’s IDVYNSO has won FDA approval in HIV. Read what the new two-drug regimen changes, where it fits, and what risks still matter.

Read More